Arcutis Biotherapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $36.88. The average 1-year stock price forecast is 40.82% higher than the current stock price, while the lowest is $34 (+29.82%) and the highest is $40 (+52.73%).

Price Target: $36.88 (+40.82%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$34	$36.88	$37	$40
Change	+29.82%	+40.82%	+41.28%	+52.73%

Analyst Ratings

The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	5	5	5	5	5	5
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $34	Buy	Reiterates	$34	+29.82%	Aug 11, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Reiterates $34 → $38	Buy	Reiterates	$34 → $38	+45.09%	Aug 6, 2026
Serge Belanger Needham	Needham	Buy Reiterates $40	Buy	Reiterates	$40	+52.73%	Aug 6, 2026
Seamus Fernandez Guggenheim	Guggenheim	Buy Reiterates $35 → $38	Buy	Reiterates	$35 → $38	+45.09%	Aug 6, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains $35	Buy	Maintains	$35	+33.64%	Aug 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

536.95M

from 376.07M

42.78%

from 376.07M

Revenue Next Year

685.52M

from 536.95M

27.67%

from 536.95M

EPS This Year

0.41

from -0.13

EPS Next Year

1.30

from 0.41

216.60%

from 0.41

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	3.69M	59.61M	196.54M	376.07M	536.95M
Revenue Growth	-	-	1,517.09%	229.74%	91.34%	42.78%
Gross Profit	-	2.93M	54.62M	177.41M	339.38M	488.44M
Gross Margin	-	79.54%	91.63%	90.27%	90.24%	90.97%
Operating Income	-206.53M	-301.63M	-241.10M	-128.40M	-12.23M	60.57M
Net Income	-206.36M	-311.46M	-262.14M	-140.04M	-16.14M	51.79M
EPS	-	-	-	-	-0.13	0.41
Forward PE	-	-	-	-	76.62	63.62
Free Cash Flow	-102.77M	-195.81M	-152.09M	-72.90M	-15.70M	75.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	548.7M
Avg	536.9M
Low	529.3M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	45.9%
Avg	42.8%
Low	40.7%

EPS Forecast

Chart

EPS	2026	2027	2028
High	0.62
Avg	0.41
Low	0.20

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-